Physician profile
Lineda A Cereste
NPI 1982388575
$1,631.40
in general payments reported to CMS, 2019-2025
15 companies · $1,346 in 2025
The $1,346 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $146 · 2024: $140 · 2025: $1,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,631.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $427.55 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $367.22 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $280.47 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $194.27 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $75.18 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $49.98 | 2024-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.84 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $37.80 | 2024-2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $31.65 | 2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $23.20 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $20.88 | 2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.59 | 2025 | Rexulti |
| Bausch Health US, LLC | $20.28 | 2025 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $17.50 | 2024 | Loreev Xr |
| Noven Therapeutics, LLC | $16.99 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lineda Cereste listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.